Plante Moran Financial Advisors’s Eton Pharmaceutcials ETON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,000
Closed -$6K 933
2024
Q3
$6K Hold
1,000
﹤0.01% 662
2024
Q2
$3.29K Hold
1,000
﹤0.01% 681
2024
Q1
$3.75K Hold
1,000
﹤0.01% 712
2023
Q4
$4.38K Hold
1,000
﹤0.01% 655
2023
Q3
$4.17K Hold
1,000
﹤0.01% 627
2023
Q2
$3.49K Hold
1,000
﹤0.01% 653
2023
Q1
$3.85K Hold
1,000
﹤0.01% 662
2022
Q4
$2.82K Hold
1,000
﹤0.01% 717
2022
Q3
$2K Hold
1,000
﹤0.01% 779
2022
Q2
$3K Hold
1,000
﹤0.01% 764
2022
Q1
$4K Hold
1,000
﹤0.01% 694
2021
Q4
$4K Hold
1,000
﹤0.01% 847
2021
Q3
$5K Hold
1,000
﹤0.01% 779
2021
Q2
$6K Hold
1,000
﹤0.01% 751
2021
Q1
$7K Hold
1,000
﹤0.01% 707
2020
Q4
$8K Buy
+1,000
New +$7.71K ﹤0.01% 649
2020
Q3
Sell
-2,000
Closed -$11K 860
2020
Q2
$11K Buy
2,000
+1,000
+100% +$4.97K ﹤0.01% 512
2020
Q1
$4K Sell
1,000
-1,000
-50% -$5.84K ﹤0.01% 591
2019
Q4
$14K Buy
+2,000
New +$12.4K ﹤0.01% 515

Other funds holding ETON

Plante Moran Financial Advisors's ETON Position: Q4 2024 in Review

Plante Moran Financial Advisors sold out of Eton Pharmaceutcials (ETON) in Q4 2024, closing a stake of 1,000 shares — an estimated $6K sold.

Plante Moran Financial Advisors first reported a position in ETON in Q4 2019 and held it in 19 quarters. The position peaked at $14K in Q4 2019. 71 funds tracked by Wall St. Rank hold ETON as of Q4 2024.

  • Plante Moran Financial Advisors reported no remaining Eton Pharmaceutcials position as of Q4 2024 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 1,000 Eton Pharmaceutcials shares in Q4 2024, an estimated $6K.
  • Plante Moran Financial Advisors first reported a position in Eton Pharmaceutcials in Q4 2019 and held it in 19 quarters.
  • Plante Moran Financial Advisors's Eton Pharmaceutcials position peaked at $14K in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q4 2024.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2024, filed 5 Feb 2025.